Garth is currently President and CEO of Mimetogen Pharmaceuticals Inc., a biotechnology company developing novel neuroprotective and neurostimulatory compounds for the treatment of ocular diseases. Prior to Mimetogen, Dr. Cumberlidge served as President & CEO of Qbiogene Inc., a company providing life sciences research products and custom cGMP manufacturing services to academic, biotechnology and pharmaceutical researchers worldwide. Cumberlidge holds degrees in Biochemistry and Genetics from the University of London (U.K.) and in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin (Germany).
Frank Kalkbrenner, MD, PhD
Frank is the Managing Director of the Boehringer Ingelheim Corporate Venture Fund. In 1997, Dr Kalkbrenner joined Schering AG as senior scientist in Experimental Dermatology. He joined Boehringer Ingelheim in 1999 and held several positions in the department of Pulmonary Research. In 2005 he took over the responsibility for the Licensing Department, and led the licensing activities of the Corporate Boehringer Ingelheim organisation. In addition, he built up the NBE Research unit at the German Research site in Biberach. Dr Kalkbrenner also serves as board member of STAT Diagnostica in Barcelona (Spain) and of Acousia Therapeutics in Tübingen (Germany). He is also a member of the supervisory and the advisory board of Inserm Transfer Initiative, a French Seed Investment Fund based in Paris.
Mrs Chahra Louafi
Chahra is the Investment Director and head of the fund for biotherapies and rare diseases at Bpifrance which she joined in 2001. She is also Vice-president of the Supervisory Board of Inserm Transfert Initiative and a member of the Supervisory Board of Cap Decisif Management. Previously she was in charge of project development and company inceptions in a private incubator for biotechnology companies. Chahra Louafi also sits on the Board of DBV Technologies, Sensorion, MedDay, Pixium Vision and Lysogene.
Mrs Catherine Boule
Catherine is a Partner at Cap Decisif, a Paris-based seed Fund, which she joined in 2003. She is also a Board Director at Axess Vision Technology, EyeBrain, Innavirvax, Eviagenics, Physikron, VitamFero, Laboratoire Watchfrog and Voluntis.
Mr. Ohad Hammer
Ohad has been a biotech analyst at Pontifax for 8 years. He is involved in identifying as well as evaluating new investment opportunities. Ohad focuses on early-stage projects and oversees scouting, due diligence and company formation. He also supports development and business development activities within Pontifax’s early-stage portfolio companies. Ohad obtained his M.S. in Biology from Tel-Aviv University and writes about small and mid-cap biotech stocks on his blog: www.orf-blog.com
Patricia Zilliox, PhD
Patricia is currently the Chief Drug Development Officer of the Clinical Research Institute, a division of the Foundation Fighting Blindness, in Columbia, MD, USA. From late 2008 until May 2011, Dr Zilliox was head of clinical development at Alcon Laboratories, where she had global accountability for planning, development, execution and management of pharmaceutical clinical programs in areas of eye diseases such as glaucoma, allergy, dry eye, infectious disease of the eye, and diseases of the retina, in particular dry and wet age-related macular degeneration. Dr Zilliox previously worked for Alcon in Europe, where she was responsible of conducting and executing the company’s European ophthalmology clinical trials.
Francine Behar-Cohen, MD, PhD, Founder of Eyevensys
Francine founded Eyevensys in December 2008. From 2013 to 2016, she was the Chief Medical Officer of the Gonin Lausanne Ophthalmology Hospital in Switzerland. She is Professor of Ophthalmology at Paris Descartes University (France), Head of the Department of Ophthalmology of Hôtel-Dieu – University of Paris Descartes Hospital, and Director of the “Physiopathology of Ocular Diseases” lab at the Cordeliers INSERM Centre. She has authored over 164 publications since 1999. Very entrepreneurially oriented, Francine also founded Eyegate Pharma in 1997.